Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,600 shares, a decrease of 93.5% from the March 31st total of 39,700 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is currently 0.2 days.

Windtree Therapeutics Trading Up 3.2 %

NASDAQ WINT opened at $5.23 on Friday. Windtree Therapeutics has a 52 week low of $4.78 and a 52 week high of $35.10. The company has a 50 day moving average price of $6.52 and a 200 day moving average price of $11.52. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 4.42. The firm has a market cap of $1.50 million, a PE ratio of -0.04 and a beta of 0.61.

Windtree Therapeutics (NASDAQ:WINT) last issued its quarterly earnings results on Tuesday, April 16th. The company reported ($13.31) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Windtree Therapeutics will post -24.93 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.